Analyst consensus rating
Edwards Lifesciences Analyst Rating: Buy
Direct answer
Edwards Lifesciences's consensus rating is Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $112.42.
Forecast evidence checked November 12, 2026.
Get free Edwards Lifesciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $105.81
- Average price target
- $112.42
- High price target
- $126.00
- Low price target
- $84.00
- Low target gap
- -20.6%
- Target upside
- +6.2%
- High target gap
- +19.1%
- Target range width
- 39.7%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Edwards Lifesciences?
Edwards Lifesciences has a verified Buy consensus. The same dataset has an average price target of $112.42.
How far are Edwards Lifesciences's low and high targets from the recorded price?
The low target implies -20.6%, while the high target implies +19.1%.
How many analysts are included in Edwards Lifesciences's consensus?
The verified consensus includes 27 analysts.
How is Edwards Lifesciences's target upside or downside calculated?
The average target of $112.42 is divided by the recorded price of $105.81, then one is subtracted to produce +6.2%. This does not guarantee a future return.
When was Edwards Lifesciences's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.